It is largely prescribed off-label as a weight loss treatment. The category of drugs is known as GLP-1s, which work by mimicking a hormone that suppresses appetite. Eli Lilly and Co (NYSE:LLY) is looking to gain ground in the space with its drug Mounjaro, which some analysts believe has the potential to surpass Novo Nordisk's offerings. Going forward, the question is whether Novo Nordisk, Eli Lilly and others can deal with supply shortages that are impacting many of their treatments in the US, the report said.